Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SMC-101-017
- Development stage
- Preclinical
- Lead developer
- Samsung Medical Center
- Modality
- Small Molecules
01
Overview
SMC-101-017 is a small molecule dual inhibitor of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) and Tyrosine Kinase with Immunoglobulin-like and EGF-like domains 2 (TIE2). Developed by researchers at Samsung Medical Center using a fragment-recombination design approach, the compound is intended for the treatment of sarcomas. In preclinical studies, SMC-101-017 demonstrated potent, time-dependent cytotoxicity against human osteosarcoma cell lines (including 143B and KHOS/NP) while maintaining selectivity by sparing myeloid cells (RAW264.7). This profile distinguishes it from approved multi-kinase inhibitors like pazopanib and regorafenib, which showed lower potency or reduced selectivity in the same models.
Beyond the preview
Go deeper on SMC-101-017.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SMC-101-017.